Shanghai Henlius Biotech, Inc. Class H · HKEX:2696
Shanghai Henlius Biotech, Inc. Class H — FY2023 Earnings Presentation
44 slides from Shanghai Henlius Biotech, Inc. Class H's earnings presentation, March 2024
Slide 1: Henlius (2696.HK) 2023 Annual Results Investor Presentation
Henlius (2696.HK) 2023 Annual Results Investor Presentation March 2024 © 2024 Henlius.
Slide 2: 2023 Business Highlights & Company Strategy
01 2023 Business Highlights & Company Strategy © 2024 Henlius.
Slide 3: Revenue Tops 5.39B RMB with Net Profit of 546M RMB
Revenue Tops 5.39B RMB with Net Profit of 546M RMB Commercial Operating Revenue BD Pipeline Capacity Cash Flow 5.39B RMB 4 50+ 48KL 1.05B RMB Commercialization BD R&D Manufacturing Financial • Achieved sustainable and • HLX10 out-licensed to Intas in • The clinical data of HLX10 for • Xuhui Site and
Slide 4: Our Mission and Vision
Biosimilars Maximize the commercialization value in China and international markets Our Mission and Vision Innovative Drugs Explore new mechanisms, new technology platforms and expand the therapeutic area coverage Affordable Innovation Reliable Quality Globalization Develop towards a biopharma with
Slide 5: Sales Growth of Marketed Biosimilars Accelerated; Pipeline Products Planned for Global Presence
The Sales Growth of Marketed Biosimilars Accelerated; Multiple Pipeline Products Planned for Global Presence • 2023 sales revenue of biosimilars reached 3.43 billion RMB, 47% YoY growth • The biosimilar pipeline covered globally popular targets such as HER2, RANKL, CTLA-4, and conducted MRCT for glo
Slide 6: Serplulimab Entered New High-growth Stage of Commercialization
Serplulimab Entered into a New High-growth Stage of Commercialization with Differentiated Advantage Clinical Differentiated 1.12B RMB Advantages Indications • 2023 sales revenue reached 1.12B RMB Serplulimab recommended by 9 Diagnosis and ES-SCLC (marketed): Treatment Guidelines of CSCO in 2023 ASTR
Slide 7: R&D for Innovative Drugs: Beyond Oncology, Expanding into New TAs
R&D for Innovative Drugs: Beyond Oncology, Expanding into New TAs Product Type & Introduction Pipeline Distribution by Stage ✓ Henlius pipeline contains 59 molecules and 18 R&D platforms with 48 innovative drugs and 11 biosimilars 35 ✓ Pipeline focuses around oncology while starting to explore new T
Slide 8: Globalization Has Entered into Substantial Development Stage
Globalization Has Entered into Substantial Development Stage (Marketed) HLX10-Serplulimab (Marketed) HLX02-Trastuzumab biosimilar • Serplulimab has been approved for 1L ES-SCLC by • HANQUYOU has marketed in 40+ countries and regions, including the EU, Southeast Indonesia’s food and drug administrati
Slide 9: Commercialization
02 Commercialization © 2024 Henlius.
Slide 10: HANQUYOU (Trastuzumab): Sales Growth 58% YoY
HANQUYOU (Trastuzumab): Sales Growth 58% YoY International quality Strong growth momentum • First approved trastuzumab biosimilar in China • First “Chinese nationality” mAb biosimilar approved In Billion RMB 2.74B RMB* in Europe • BLA under FDA review; expected to be the first “Chinese nationality”
Slide 11: Excellent Performance of HANQUYOU
Excellent Performance of HANQUYOU Strengthen product Higher sales per capita The only Trastuzumab Bold expansion into differentiation for than domestic peers with two specifications broad market competitive advantages Sales Per Capita1 • 2 specifications were • In 2023, the competition has • Trastuz
Slide 12: HANSIZHUANG (Serplulimab): First Approved PD-1 mAb for 1L SCLC
HANSIZHUANG (Serplulimab): First Approved PD-1 mAb for 1L SCLC Differentiated strategies to seize the Widespread recognition market • MAA for 1L ES-SCLC indication is under EMA review • Developed differentiated marketing strategies and focused on SCLC to rapidly increase market share 1.12B RMB • Rec
Slide 13: HANSIZHUANG Commercialization Highlights
HANSIZHUANG Commercialization Highlights Differentiation strategy to tackle First-class Commercialization Efficiency challenges and win opportunities Differentiation Strategy Outstanding Focus on SCLC Achievements (15-20% of total lung cancer patients) • Sales outperformed most of the competing • Ac
Slide 14: HANBEITAI (Bevacizumab): Commercialization Acceleration in 2023
HANBEITAI (Bevacizumab): Commercialization Acceleration in 2023 Acceleration on market access Exploration for new medication and penetration methods 119M RMB • Covered by NRDL in 31 provinces, and • The only bevacizumab biosimilars with phase III completed tendering and procurement platform clinical
Slide 15: HANLIKANG (Rituximab): Strengthen the Market Leader Position
HANLIKANG (Rituximab): Strengthen the Market Leader Position Acceleration on market access Commercialization Progress and penetration • Approved in February 2019 as the first • Jiangsu Fosun, a subsidiary of Fosun approved biosimilar in China, the first Pharma, is responsible for HANLIKANG’s 541M RM
Slide 16: HANDAYUAN (Adalimumab): Entered Autoimmune Disease Area
HANDAYUAN (Adalimumab): Entered Autoimmune Disease Area Improve patients’ availability and Work with partners to penetrate the accessibility market • Henlius’ first autoimmune disease product • Jiangsu Wanbang is responsible for China local sales 59M RMB • Covered by NRDL and completed tendering and
Slide 17: Business Development
03 Business Development © 2024 Henlius.
Slide 18: 2023 Major Business Development Projects
2023 Major Business Development Projects Out-licensing In-licensing PT Kalbe Genexine Biologics Accord Healthcare Limited Boston Oncology, LLC Sermonix Pharmaceuticals Subsidiary of Intas Pharmaceuticals Limited (Contract signing date: 2023/08/25) (Contract signing date: 2023/10/27) (Contract signin
Slide 19: In-licensing Focus: Expand Portfolio into Sub-types of Breast Cancer
In-licensing Focus: Leverage BD to Expand Portfolio into Different Sub-types of Breast Cancer Type HR+/ Lasofoxifene (small molecule SERM*): Breast cancer HER2+ • Lasofoxifene has tissue selectivity to the biological HER2- activities of estrogen receptor (ER); ER shows products inhibitory activity i
Slide 20: Out-licensing Focus: International Quality Biosimilars Scale up across the Globe
Out-licensing Focus: Henlius’ International Quality Biosimilars Scale up across the Globe Market Size of Originators and Marketed Biosimilars Biosimilars with existing out-licensing partners Biosimilars to be out-licensed ex-China Global sales in 2023 (M USD) Global sales in 2023 (M USD) HLX17- HLX0
Slide 21: Research & Development
04 Research & Development 21 © 2024 Henlius.
Slide 22: Product Pipeline
Product Pipeline IND Phase I Phase II Phase III NDA Marketed (1) (2) (1) (1) (1) (1) HLX51 HLX10 (serplulimab)+HLX60 HLX10 (serplulimab)+HANBEITAI HLX10 (serplulimab)+chemo HLX10 (serplulimab)+chemo HANSIZHUANG (serplulimab) OX40 PD-1+GARP PD-1+VEGF PD-1 PD-1 PD-1 Solid tumors, lymphoma Solid tumors
Slide 23: Clinical Pipeline Milestones: 2023 Full-Year Review
Clinical Pipeline Milestones: 2023 Full-Year Review 2023 HLX10 HLX10 HLX10 ES-SCLC1 ES-SCLC nsNSCLC2 1L (EU) 1L (Indonesia, Myanmar, Cambodia, 1L (China) Malaysia, Thailand, Singapore) NDA/BLA/MAA Submission HLX10 HLX07+HLX10 HLX07+HLX10 sqNSCLC3 ESCC4 sqNSCLC Final OS results 1L, 2L and late-line 1
Slide 24: Clinical Pipeline Milestones: Expected in 2024
Clinical Pipeline Milestones: Expected in 2024 2024H1 2024H2 HLX10 HLX10 HLX10 HLX14 MSI-H solid tumors ESCC2 ES-SCLC3 HLX10 HLX10 HLX10 PMOP1 Late-line (Hong Kong 1L (Macao sqNSCLC4 MSI-H solid tumors ESCC2 1L (US, Vietnam, UK, (EU & US) SAR, Macao SAR) SAR) India) 1L (India) Late-line (India) 1L (
Slide 25: Clinical Data of HLX10-015-CRC301
Clinical Data of HLX10-015-CRC301 Data cut-off date: 2023/06/01; median follow-up duration: 17.7 months • The latest clinical data of the phase II/III results (HLX10-015-CRC301) of HANSIZHUANG (HLX10, serplulimab)+HANBEITAI (HLX04, bevacizumab)+XELOX for 1L mCRC (metastatic colorectal cancer) treatm
Slide 26: Serplulimab: Targeting Differentiated Indications
Serplulimab: Targeting Differentiated Indications According to the baseline data analysis of 649 subjects in the Checkmate, 60% advanced GC patients had CPS ≥ 5. The trial design had focused on PD-L1-positive patients (CPS ≥ 5) from Gastric Cancer the very beginning. Serplulimab aims to be the world
Slide 27: HLX22: Potential to Change the SOC of 1L GC
HLX22: Potential to Change the SOC of 1L GC HLX22 (HER2) • HLX22 targets at different epitopes within domain IV of Her2 Anti-HER2 mAb • PDx data shows HLX22 & Trastuzumab combo has more advantages than Trastuzumab & Pertuzumab combo in GC • Current SOC of 1L mGC/GJC treatment Trastuzumab + chemo app
Slide 28: Clinical Data of HLX22-GC-201
Clinical Data of HLX22-GC-201 Data cut-off date: 2023/07/30 ; median follow-up duration: 14.3 months • The clinical data of Phase II study (HLX22-GC-201) of HLX22 (an innovative anti-HER2 mAb)+HANQUYOU (HLX02, trastuzumab)+XELOX for the 1L HER2-positive gastric/gastroesophageal junction (G/GEJ) canc
Slide 29: Pre-clinical Assets
4.1 Pre-clinical Assets © 2024 Henlius.
Slide 30: HLX43 (PD-L1 ADC) Presented Excellent Preclinical Efficacy Data in ESMO
HLX43 (PD-L1 ADC) Presented Excellent Preclinical Efficacy Data in ESMO and Entered into Clinical Phase I HLX43 shows no immunotoxicity HLX34 exhibits excellent anti-tumor ESMO 2023 FPN: 693P towards PD-L1 positive human APCs efficacy in vivo Title A A • Preclinical activity of HLX43, a PD-L1-target
Slide 31: HLX42 (EGFR ADC) Preclinical Data and FDA Fast Track Designation
HLX42 (EGFR ADC) Presented Excellent Preclinical Data in ESMO and Was Granted Fast Track Designation by FDA ESMO 2023 FPN: 683P Title A D • Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for Cetuximab or TKI resistant cancer In vivo efficacy results In vivo efficacy results • In in viv
Slide 32: Three Major Preclinical Platforms Drive Development of Representative Molecules
Three Major Preclinical Platforms Drive Full-Speed Development of Representative Molecules Protein drug discovery and engineering HanjugatorTM : AI4T (AI for Therapeutics) to drive platform to enable innovative therapeutic Modular ADC toolbox and development innovative drug discovery for oncology, R
Slide 33: HLX99: First-In-Class Anti-ALS/PD Drug Candidate
HLX99: “First-In-Class” anti-ALS/PD Drug Candidate ⚫ Indication Amyotrophic Lateral Sclerosis (ALS); MOA of the Anti-Neurodegenerative Diseases (NDDs) Drug Candidate HLX99 Parkinson’s disease (PD) ⚫ Entity Project information Immune Patent filed. IND to be approved in China modulation in 2024 H1 ⚫ M
Slide 34: Manufacturing
05 Manufacturing © 2024 Henlius.
Slide 35: International Leading Capabilities on Manufacturing and Quality Management
International Leading Capabilities on Manufacturing and Quality Management Xuhui Site Songjiang Songjiang L L 1st Plant 2nd Plant 0 0 00 00 4, 4, 2 2 • Manufacturing capacity optimization: • Increasing supply of HANQUYOU • Plant construction for Phase I & II trials: The scale of commercial GMP batch
Slide 36: Operation Excellence and Continuous Innovation
Operation Excellence and Continuous Innovation Technical Innovation Lean Operations • Reached key milestone of using Lean • 30+ on-going lean operations projects domestic production consumables with ~10M RMB expected annualized Operations and completed commercial scale returns process validation • T
Slide 37: 2023 Financial Review
06 2023 Financial Review © 2024 Henlius.
Slide 38: 2023 Full Year Revenue of RMB 5.39 Billion with 67.8% YoY
2023 Full Year Revenue of RMB 5.39 Billion with 67.8% YoY Revenue (in Billion RMB) Product Sales (in Billion RMB) 2023 Revenue Breakdown (in Million RMB) 2023 2022 2023 revenue for illustration % 2023 share % 67.8% 70.2% 5.39 4.55 91.1% 79.0% 50.7% 3.21 2.68 2737 1731 20.8% 1.68 1.49 1120 15.6% 9.6%
Slide 39: Achieved Profitability in 2023 with RMB ~1.05B Operating CF
Achieved Profitability in 2023 with RMB ~1.05B Operating CF Net profit (net loss): turned into profitability (in Million RMB) R&D related investment (in Million RMB) Net profit (net loss) margin Net profit (net loss) Cost of Services Provided* Capitalized Expensed 10.1% 2523 546 340 2111 1890 126 78
Slide 40: Financial Highlights
Financial Highlights Financial Data (selected) 2023 2022 YoY Growth Unit In Million RMB % of revenue In Million RMB % of revenue % Revenue 5,394.9 100.0% 3,214.7 100.0% 67.8% Product sales 4,553.5 84.4% 2,675.4 83.2% 70.2% BD and other revenue 841.4 15.6% 539.4 16.8% 56.0% Cost of sales (1,476.1) (2
Slide 41: 2024 Performance Outlook
07 2024 Performance Outlook © 2024 Henlius.
Slide 42: Our Goals for 2024
Our Goals for 2024 Revenue: maintain rapid growth in overall revenue by continuously promoting clinical advantage of HANSIZHUANG and HANQUYOU Profitability: improve P&L level, and consolidate profitability from internal operation Cashflow: positive OCF generated for three consecutive years; further
Slide 43: Disclaimer
声明 Disclaimer • 复宏汉霖、陈述人或提供人对本文件内容(文件内容亦有可能包括前瞻性陈述)均不做出明示或默示的保证、声明或陈述(包括但不限于:本内容针对为任意特定目的而关于内容 所具有的及时性、通用性、精确性的声明,或者关于使用本文件内容所获得信息无误可信的声明)。如因有关内容存在错误、遗漏或失准之处而引致的行为或结果,复宏汉霖、陈 述人或提供人对此不承担责任。 • 本文件及其中所包含内容的所有权利包括版权均由复宏汉霖独家所有,其中相关的“Henlius”和“复宏汉霖”字样、图案及相关LOGO标识均为复宏汉霖合法所有的字号、商标 和标识。未经复宏汉霖书面同意,任何第三方不得以包括转
Slide 44: © 2024 Henlius.
Q | Henlius #25 ARIE ANR (HE RY me Reliable Quality Affordable Innovation
Shanghai Henlius Biotech — FY2023 Earnings Presentation on 6ix